Are you Dr. Ross?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 76 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
44 Binney Street
D1230
Boston, MA 02115Phone+1 617-632-3237
Summary
- Dr. Robert Ross, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Dana-Farber Cancer Institute and is a Clinical Instructor in Medicine at Dana-Farber Cancer Institute.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2005
University of California (San Francisco)Residency, Internal Medicine, 1999 - 2002
Columbia University Vagelos College of Physicians and SurgeonsClass of 1999
Certifications & Licensure
MA State Medical License 2003 - 2022
Clinical Trials
- Dose Escalation of IPI-493 in Hematologic Malignancies Start of enrollment: 2010 Jun 01
Publications & Presentations
PubMed
- 59 citationsMulticenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.William Oh, Matthew D. Galsky, Walter M. Stadler, Sandy Srinivas, Franklin Chu
Urology. 2011-09-01 - 152 citationsDouble-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial CancerToni K. Choueiri, Robert W. Ross, Susanna Jacobus, Ulka N. Vaishampayan, Evan Y. Yu
Journal of Clinical Oncology. 2012-02-10 - 262 citationsActivity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.Lecia V. Sequist, Scott N. Gettinger, Neil Senzer, Renato G. Martins, Pasi A. Jänne
Journal of Clinical Oncology. 2010-11-20
Press Mentions
Chutes & Ladders—After Verastem Pit Stop, Bluebird Vet Neumann Lands at KiteFebruary 12th, 2021
Surface Oncology to Present at the 40th Annual Cowen Healthcare ConferenceFebruary 25th, 2020- Clasp Emerges with $150M Series a Financing to Advance T Cell EngagersMarch 21st, 2024
- Join now to see all
Professional Memberships
- Member
